Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates
This article was originally published in The Pink Sheet Daily
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.
You may also be interested in...
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.
Aileron’s stapled peptides spark investment interest from four big pharma VC arms.